NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
25.59
+0.67 (2.69%)
Sep 2, 2026, 4:00 PM EDT - Market closed
NAMS Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 424.15 | 490 | 771.74 | 340.45 | 467.73 | 60.38 |
Short-Term Investments | 209.7 | 146.24 | 62.45 | - | - | - |
Cash & Short-Term Investments | 633.85 | 636.24 | 834.19 | 340.45 | 467.73 | 60.38 |
Cash Growth | -14.25% | -23.73% | 145.03% | -27.21% | 674.64% | 527.92% |
Other Receivables | 5.35 | 23.15 | 21.31 | 1.88 | 2.07 | 4.88 |
Receivables | 5.35 | 23.15 | 21.31 | 1.88 | 2.07 | 4.88 |
Prepaid Expenses | 18.65 | 14.99 | 7.92 | 4.46 | 8.18 | 1.7 |
Restricted Cash | 1.36 | 1.32 | - | - | - | - |
Total Current Assets | 659.21 | 675.7 | 863.41 | 346.79 | 477.98 | 66.96 |
Property, Plant & Equipment | 0.49 | 0.57 | 0.67 | 0.1 | 0.15 | 0.22 |
Long-Term Investments | 44.41 | 92.61 | - | - | - | - |
Other Intangible Assets | 0.34 | 0.41 | 0.53 | 0.17 | 0.21 | - |
Other Long-Term Assets | - | - | - | 0.04 | 0.16 | - |
Total Assets | 704.45 | 769.28 | 864.62 | 347.1 | 478.5 | 67.99 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.42 | 8.97 | 4.74 | 16.92 | 11.85 | 7.07 |
Accrued Expenses | 10.28 | 15.42 | 13.61 | 11.4 | 6.12 | 4.1 |
Current Portion of Leases | 0.03 | 0.14 | 0.25 | 0.06 | 0.07 | 0.06 |
Current Unearned Revenue | 2.8 | 3.99 | 6.01 | 8.94 | 13.87 | - |
Other Current Liabilities | 54.45 | 57.27 | 82.31 | 12.57 | 4.15 | - |
Total Current Liabilities | 72.97 | 85.79 | 106.92 | 49.9 | 36.06 | 11.24 |
Long-Term Leases | 0.06 | 0.07 | 0.2 | - | 0.06 | 0.13 |
Long-Term Unearned Revenue | - | - | - | 1.02 | 4.79 | - |
Other Long-Term Liabilities | - | - | - | 7.79 | 7.52 | - |
Total Liabilities | 73.03 | 85.85 | 107.12 | 58.7 | 48.43 | 11.36 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 14.74 | 14.28 | 13.44 | 10.17 | 10.06 | 0.13 |
Additional Paid-In Capital | 1,488 | 1,427 | 1,298 | 590.77 | 555.63 | 95.26 |
Retained Earnings | -874.97 | -762.39 | -558.57 | -316.97 | -140.04 | -39.44 |
Comprehensive Income & Other | 3.86 | 4.79 | 4.47 | 4.42 | 4.42 | 0.67 |
Shareholders' Equity | 631.42 | 683.43 | 757.5 | 288.39 | 430.07 | 56.63 |
Total Liabilities & Equity | 704.45 | 769.28 | 864.62 | 347.1 | 478.5 | 67.99 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.08 | 0.2 | 0.45 | 0.06 | 0.13 | 0.19 |
Net Cash (Debt) | 678.18 | 728.65 | 833.74 | 340.39 | 467.6 | 60.19 |
Net Cash Growth | -13.39% | -12.61% | 144.94% | -27.21% | 676.83% | - |
Net Cash Per Share | 5.60 | 6.15 | 8.84 | 4.14 | 24.65 | 5.48 |
Filing Date Shares Outstanding | 119.54 | 114.98 | 109.82 | 89.27 | 81.77 | 11.33 |
Total Common Shares Outstanding | 117.65 | 114.4 | 108.06 | 82.47 | 81.56 | 11.33 |
Working Capital | 586.23 | 589.91 | 756.5 | 296.89 | 441.92 | 55.72 |
Book Value Per Share | 5.37 | 5.97 | 7.01 | 3.50 | 5.27 | 5.00 |
Tangible Book Value | 631.08 | 683.02 | 756.97 | 288.22 | 429.86 | 56.63 |
Tangible Book Value Per Share | 5.36 | 5.97 | 7.00 | 3.49 | 5.27 | 5.00 |
Machinery | - | - | - | - | - | 0.04 |